NASDAQ · Biotechnology

Palvella Therapeutics, Inc. (PVLA) Stock

$138.77 +5.66% NASDAQ: PVLA Healthcare

Valuation

MetricValue
Price$138.77
Market Cap$1.99B
P/E Ratio-28.56
P/B Ratio9.13
P/S Ratio0.00
EPS (TTM)$-3.71
52-Week High$161.38
52-Week Low$60.49
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-47.84%
ROA-24.34%
ROCE-23.90%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio5.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$31.0M$26.0M$0$0$0
Operating Profit$-52.0M$-43.0M$-12.0M$-14.0M$-39.0M
Net Profit$-46.0M$-33.0M$19.0M$-17.0M$-42.0M
EPS$-56.69$-29.61$14.74$-7.83$-3.71
Op Margin-165.0%-167.8%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$154.0M$17.0M$8.0M$88.0M$60.0M
Total Liabilities$103.0M$40.0M$11.0M$26.0M$32.0M
Cash$118.0M$16.0M$7.0M$84.0M$58.0M
Borrowings$15.0M$0$0$0$1.0M

Latest News

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN Insider Monkey · Jul 15, 2026 Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors GlobeNewswire · Jun 30, 2026 Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations GlobeNewswire · Jun 29, 2026 What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally Motley Fool · Jun 27, 2026 Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy InvestorsHub · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-15.0M$-14.0M$-11.0M$-25.0M
Investing Cash Flow$-2.0M$0$0$0$0
Financing Cash Flow$0$0$5.0M$9.0M$-1.0M
Net Cash Flow$47.0M$-5.0M$-31.0M$76.0M$-26.0M
Free Cash Flow$-9.0M$-15.0M$-14.0M$-11.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.98
EV / EBITDA-35.82
FCF Yield-1.85%
Quick Ratio21.18
Interest Coverage-7.60
Return 1Y272.94%
Return 3Y678.91%
Return 5Y-46.84%

Ownership

Insiders Held11.65%
Institutions Held97.04%
Institutions Float Held109.84%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC1,153,4962026-03-31
First Light Asset Management, LLC980,7582026-03-31
BVF Inc.960,9892026-03-31
Frazier Life Sciences Management, L.P. 882,4002026-03-31
Blackrock Inc.686,8532026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
DERMJourney Medical Corporation $6.31 +6.05% -29.64 $173.66M 0.00%
QNRXQuoin Pharmaceuticals, Ltd. $4.40 +2.92% -0.25 $8.84M 0.00%
SLGLSol-Gel Technologies Ltd. $71.77 +2.03% -12.77 $234.62M 0.00%
VRCAVerrica Pharmaceuticals Inc. $4.11 -1.67% -2.52 $70.60M 0.00%

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is led by CEO Wesley H. Kaupinen, employs 14 people, headquartered in US, publicly traded since 2015.

Palvella Therapeutics, Inc. (PVLA) stock trades at $138.77 with a market capitalization of $1.99B. The stock is valued at a price-to-earnings (P/E) ratio of -28.56, price-to-book of 9.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $60.49 and $161.38, and currently trades 14.0% below its 52-week high.

On profitability, Palvella Therapeutics, Inc. generates a return on equity (ROE) of -47.84%, return on capital employed of -23.90%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides